Phase 2 Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for NSCLC Leptomeningeal Disease
ClinicalTrials.gov Studies
Summary
NCT07551414 is a prospective Phase 2 study evaluating Zorifertinib combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy in patients with Non-small Cell Lung Carcinoma (NSCLC) and leptomeningeal metastasis who have progressed after third-generation EGFR-TKI therapy. The study specifies conditions (NSCLC, Leptomeningeal Metastasis, EGFR-TKI Sensitizing Mutation) and interventions (Zorifertinib Plus Intra-Ommaya CSF Chemotherapy). This is a clinical trial registration record providing public access to study details and does not impose compliance obligations on any entity.
“A Prospective Study of Zorifertinib Combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy for Leptomeningeal Progression in NSCLC Patients After Third-Generation EGFR-TKI Therapy”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NCT07551414 is a prospective Phase 2 clinical trial registration for Zorifertinib combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy, targeting NSCLC patients with leptomeningeal metastasis and EGFR-TKI sensitizing mutations who have progressed after third-generation EGFR-TKI therapy. The study is registered with conditions and interventions clearly defined.
Pharmaceutical and biotechnology entities involved in EGFR-TKI or NSCLC leptomeningeal disease research may find this trial relevant to competitive landscape monitoring and partnership or licensing considerations. Clinical investigators and trial sponsors in this therapeutic area should be aware of this active Phase 2 study.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
Phase 2 NCT07551414 Kind: PHASE2 Apr 24, 2026
Abstract
A Prospective Study of Zorifertinib Combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy for Leptomeningeal Progression in NSCLC Patients After Third-Generation EGFR-TKI Therapy
Conditions: NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis, EGFR-TKI Sensitizing Mutation, Zorifertinib
Interventions: Zorifertinib Plus Intra-Ommaya CSF Chemotherapy
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.